Navigation Links
Stem cells: Deathly awakening by interferon
Date:2/12/2009

After injuries with blood loss, the body quickly needs to restore the vital blood volume. This is accomplished by a special group of stem cells in the bone marrow. These hematopoietic stem cells remain dormant throughout their lives and are only awakened to activity in case of injury and loss of blood. Then they immediately start dividing to make up for the loss of blood cells. This has recently been shown by a group of scientists headed by Professor Andreas Trumpp of DKFZ.

Dormancy is an important protection mechanism of stem cells. First, it protects their genetic material from genetic alterations, which happen primarily during cell division. In addition, dormancy helps them escape attacks of many cytotoxins, which act only on dividing cells.

Scientists were still puzzling over which signaling molecules actually wake up stem cells from their dormancy. Andreas Trumpp and Marieke Essers from his team have now reported in Nature that interferon-alpha, a messenger substance of the immune system, acts like an alarm clock for hematopoietic stem cells. The scientists have thus shown for the first time that interferon-alpha can have a direct influence on the function of stem cells.

Interferon-alpha is released by immune cells when the organism is threatened by bacteria or viruses. The scientists triggered interferon production in mice by administering a substance that simulates a viral infection to the animals. Subsequently, there was a great increase in the division rate of hematopoietic stem cells. In control animals that were unable to process the interferon signals, the substance did not lead to an awakening of the stem cells.

The investigators obtained further proof of the effect of interferon-alpha using a drug called 5-fluorouracil, a cytotoxic substance frequently used for treating breast or bowel cancer. Dormant stem cells are resistant to the drug, which unfolds its effect only during division. However, if animals are given interferon-alpha prior to treatment with 5-fluorouracil, they die of anemia after a short time. This is because prior treatment with interferon forces quiescent stem cells into cell division, which sensitizes them for the effect of 5-FU and kills them. Thus, there are soon no more stem cells to keep up the supply of short-lived mature blood cells such as erythrocytes and blood platelets.

What researchers find particularly exciting about this finding is the prospect that the newly found working mechanism might help improve cancer treatment: "Using interferon-alpha, we might be able to wake up from dormancy not only hematopoietic stem cells but also tumor stem cells and, thus, break their frequently observed resistance to many anticancer drugs," Andreas Trumpp speculates.

A clinical observation already suggests that this assumption is more than just wishful thinking: Patients suffering from a type of blood cancer called chronic myelogenous leukemia who are treated with a drug called Gleevec almost always relapse after drug treatment has ended. Several patients were given interferon-alpha prior to the Gleevec treatment. Surprisingly, these patients experienced long relapse-free phases without any medication. "We believe that the leukemia stem cells were awakened by the interferon administration and, thus, were sensitized to elimination by Gleevec," Andreas Trumpp explains.


'/>"/>

Contact: Dr. Sibylle Kohlstdt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. Cancer stem cells: know thine enemy
2. Tai Chi & Qigong will play an important role in global awakening. - A New Earth, Eckhart Tolle, (Oprahs Book Club)
3. HALT-C researchers: Interferon as long-term treatment for hepatitis C not effective
4. Interferon needed for cells to remember how to defeat a virus, UT Southwestern researchers report
5. Only Half of MS Patients Respond to Interferon Therapy
6. Interferon Reduces, Eliminates Viral Infections in Heart Failure Patients
7. Study shows that high-dose, high-frequency interferon produces no additional benefit
8. GenOdyssee Receives Notice of Allowance from U.S. Patent Office for Improved Interferon-Alpha Aimed at Hepatitis C
9. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
10. Interferon does not slow or stop hepatitis C from worsening, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... A study by the founder of ... colleague, Sudeep Roy, MD, was recently published in the American Journal of Cosmetic ... details Drs. Buckingham and Roy’s study on the use of Electro Lube during the ...
(Date:3/27/2017)... ... March 27, 2017 , ... Buzzies parent company, The TouchPoint ... Rent the Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her pitch about ... , Project Entrepreneur’s second annual venture competition ignites bold ideas by providing women ...
(Date:3/27/2017)... Niles, IL (PRWEB) , ... March 27, 2017 ... ... testing systems, recently received the CE Certificate of Conformity for the Smart System® ... meet or exceed the highest industry standards and specifications such as ANSI, ISO ...
(Date:3/27/2017)... ... March 27, 2017 , ... American Veterinarian™, ... coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, a business ... the April edition of American Veterinarian™. , “We look forward to ...
(Date:3/27/2017)... ... March 27, 2017 , ... Metabolism and hormone ... Women’s Excellence will help patients lose weight and keep it off. , The ... at Women's Excellence will measure BMI, body fat composition, and Calcium and Magnesium ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... and BOSTON , March 27, ... global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of innovative therapies based upon tetracycline ... of sarecycline for the treatment of moderate to ... endpoints. Sarecycline is a once-daily, oral, narrow spectrum ...
(Date:3/27/2017)... 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), a ... liver diseases in children, today reported financial results ... December 31, 2016 and provided an update on ... to make progress during the fourth quarter of ... our non-human primate safety study, and with our lead ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... offering. ... The Cell Therapy Manufacturing Market, 2017-2027 report provides an extensive ... and focuses both on contract manufacturers and cell therapy developers ... as viable alternatives to conventional treatment options. ...
Breaking Medicine Technology: